Dexcom cuts guidance as Q2 revenue falls short of estimates; shares slump
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
DexCom (DXCM) PT Lowered to $145 at RBC Capital
July 26, 2024 6:34 AM EDTRBC Capital analyst Shagun Singh lowered the price target on DexCom (NASDAQ: DXCM) to $145.00 (from $165.00) while maintaining a Outperform rating.
The analyst comments "DXCM delivered Q2 results with a 3% sales miss, but 10% EPS beat. Three factors impacted sales: below expectations US salesforce... More
Baird Downgrades DexCom (DXCM) to Neutral
July 26, 2024 6:18 AM EDTBaird analyst Jeff Johnson downgraded DexCom (NASDAQ: DXCM) from Outperform to Neutral with a price target of $80.00 (from $161.00).
The analyst comments "Downgrading to Neutral/lowering price target to $80. We struggle to fully understand last night's 2Q miss/sizable cut to 2024... More
DexCom (DXCM) PT Lowered to $95 at UBS
July 26, 2024 5:57 AM EDTUBS analyst Danielle Antalffy lowered the price target on DexCom (NASDAQ: DXCM) to $95.00 (from $163.00) while maintaining a Buy rating.
The analyst comments "Shares traded down ~37% after-hours due to DXCM's ~3.5% top-line sales miss and now lower (~$300M) FY24 guidance with full-year sales expected to grow +11-13% organic vs. +17-21%, previously. And while this comes as quite a surprise to us given our view that CGM (Continuous Glucose Monitoring)... More
DexCom (DXCM) PT Lowered to $89 at Canaccord Genuity
July 26, 2024 5:40 AM EDTCanaccord Genuity analyst William J. Plovanic lowered the price target on DexCom (NASDAQ: DXCM) to $89.00 (from $145.00) while maintaining a Buy rating.
The analyst comments "Bottom line: Dexcom reported a surprising Q2 topline miss, and guidance reset, with revenue of $1,004M (+15.3% Y/Y) missing both our $1,049M estimate and consensus of $1,037M. On... More
